Lantern Pharma Inc LTRN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-11 |
| Shares Out. | 14,940,000 |
| Website | lanternpharma.com ↗ |
| Phone | 13026587581 |
| Employees | 16 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$7.1M |
| Free Cash Flow | -$14.1M |
| Total Assets | $8.6M |
| Total Liabilities | $11.8M |
| Equity | -$3.2M |
About Lantern Pharma Inc
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Lantern Pharma Inc is a publicly traded company under the ticker symbol LTRN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-11-01)